Menu Search
Equities

Eurobio Scientific SA

E8TN:FRA

Eurobio Scientific SA

Actions
  • Price (EUR)14.12
  • Today's Change0.02 / 0.14%
  • Shares traded211.00
  • 1 Year change-12.41%
  • Beta--
Data delayed at least 15 minutes, as of Apr 30 2024 14:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Eurobio Scientific SA, formerly Diaxonhit, is a France-based biotechnology company engaged in the field of in-vitro diagnostic. It is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The Company owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. It consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. It has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. It operates through Genbio and Eurobio Capforce Plus.

  • Revenue in EUR (TTM)128.01m
  • Net income in EUR7.91m
  • Incorporated1997
  • Employees304.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ALERS:PAR since
announced		Transaction
value
Diagnostic International Distribution SpAAnnounced13 Jun 202313 Jun 2023Announced2.13%--
Data delayed at least 15 minutes, as of Apr 30 2024 16:35 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.